Detection of Immunotoxic Gluten Peptides in Feces (CELIQK2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01478867|
Recruitment Status : Completed
First Posted : November 23, 2011
Last Update Posted : November 24, 2011
|Condition or disease||Intervention/treatment|
|Celiac Disease||Other: Detection of gluten in feces|
Certain immunotoxic peptides from gluten are resistant to gastrointestinal digestion and can interact with celiac patient factors to trigger immunological response. Gluten-free diet (GFD) is the only effective treatment for celiac disease (CD) and its compliance should be monitored to avoid accumulative damage. However, practical methods to monitor diet compliance and to detect the origin of an outbreak of celiac clinical symptoms are not available.
This study assesses the capacity to determine the gluten ingestion, and to monitor the GFD compliance in celiac patients by detection of gluten and gliadin 33-mer equivalent peptidic epitopes in human feces.
|Study Type :||Observational|
|Actual Enrollment :||53 participants|
|Official Title:||Phase 0 Monitoring of Gluten-free Diet Compliance in Celiac Patients by Assessment of Gliadin 33-mer Equivalent Epitopes in Feces|
|Study Start Date :||April 2011|
|Actual Study Completion Date :||July 2011|
Other: Detection of gluten in feces
Detection of Gluten in Feces
- Monitoring of gluten-free diet compliance in celiac patients [ Time Frame: April-July 2011 (3 months) ]Usual gluten diet for celiac (home diet not modified for this trial)
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01478867
|Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville|
|Seville, Spain, 41012|
|Principal Investigator:||Carolina Sousa, Professor||University of Seville, Spain|